Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 4/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.35 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.32 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.32 |
| ▸ | TNF | P01375 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL519829 | 0.90 | KCNN4 (0.37) | HCRTR1HCRTR2KCNN4P2RX7 | |
| SCHEMBL10258727 | 0.85 | NR1I2 (0.41) | KCNN4METP2RX7NR1I2 | |
| SCHEMBL10258535 | 0.85 | MET (0.36) | HCRTR1HCRTR2KCNN4METP2RX7 | |
| SCHEMBL10258520 | 0.83 | MET (0.38) | KCNN4METP2RX7NR1I2 | |
| SCHEMBL10266959 | 0.82 | ALDH1A1 (0.37) | HCRTR1HCRTR2KCNN4MET | |
| SCHEMBL7792887 | 0.81 | KCNN4 (0.38) | HCRTR1HCRTR2KCNN4P2RX7NR1I2 | |
| SCHEMBL10259058 | 0.78 | MET (0.33) | HCRTR1HCRTR2MET | |
| SCHEMBL16625716 | 0.76 | KDM4E (0.40) | — | |
| SCHEMBL518986 | 0.75 | KCNN4 (0.40) | KCNN4P2RX7NR1I2 | |
| SCHEMBL10258608 | 0.74 | ALOX15 (0.36) | HCRTR1HCRTR2P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170114044-A1 | PYRIDAZINONE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS AND METHODS OF TREATING DISORDERS | TAKEDA PHARMACEUTICALS CO (JP) | 2017-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114044-A1 | PYRIDAZINONE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS AND METHODS OF TREATING DISORDERS | PDE3A, PDE5A, PDE3B | HCRTR1 2757/4885HCRTR2 3090/4885KCNN4 963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.